Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD
(2008) In Blood 111(7). p.3531-3539- Abstract
- We have prospectively evaluated the biologic response to desmopressin in 77 patients with type 1 von Willebrand disease (VWD) enrolled within the Molecular and Clinical Markers for the Diagnosis and Management of type 1 VWD project. Complete response to desmopressin was defined as an increase of both ristocetin cofactor activity (VWF:RCo) and factor VIII coagulant activity (FVIII:C) to 50 IU/dL or higher and partial response as VWF: RCo or FVIII:C lower than 50 IU/dL after infusion, but at least 3-fold the basal level. Complete response was observed in 83% of patients; partial in 13%; and no response in 4%. Patients with some abnormality of VWF multimeric pattern had significantly lower basal FVIII:C and VWF, lower VWF:RCo/Ag ratio, and... (More)
- We have prospectively evaluated the biologic response to desmopressin in 77 patients with type 1 von Willebrand disease (VWD) enrolled within the Molecular and Clinical Markers for the Diagnosis and Management of type 1 VWD project. Complete response to desmopressin was defined as an increase of both ristocetin cofactor activity (VWF:RCo) and factor VIII coagulant activity (FVIII:C) to 50 IU/dL or higher and partial response as VWF: RCo or FVIII:C lower than 50 IU/dL after infusion, but at least 3-fold the basal level. Complete response was observed in 83% of patients; partial in 13%; and no response in 4%. Patients with some abnormality of VWF multimeric pattern had significantly lower basal FVIII:C and VWF, lower VWF:RCo/Ag ratio, and less complete responses to desmopressin than patients with a normal multimeric pattern (P =.002). Patients with mutations at codons 1130 and 1205 in the D'-D3 domain had the greatest relative increase, but shortest FVIII and VWF half-lives after infusion. Most partial and nonresponsive patients had mutations in the A1-A3 domains. Response to desmopressin in these VWD patients seemed to be associated with the location of the causative mutation. The presence of subtle multimeric abnormalities did not hamper potential clinically useful responses, as in typical type 1 VWD. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1182688
- author
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 111
- issue
- 7
- pages
- 3531 - 3539
- publisher
- American Society of Hematology
- external identifiers
-
- wos:000254569300040
- scopus:43549097149
- ISSN
- 1528-0020
- DOI
- 10.1182/blood-2007-08-109231
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200), Paediatrics (Lund) (013002000)
- id
- 3a6e4b8c-bc31-4b94-9be4-bc116ee03e3c (old id 1182688)
- date added to LUP
- 2016-04-01 11:48:21
- date last changed
- 2022-03-28 03:20:59
@article{3a6e4b8c-bc31-4b94-9be4-bc116ee03e3c, abstract = {{We have prospectively evaluated the biologic response to desmopressin in 77 patients with type 1 von Willebrand disease (VWD) enrolled within the Molecular and Clinical Markers for the Diagnosis and Management of type 1 VWD project. Complete response to desmopressin was defined as an increase of both ristocetin cofactor activity (VWF:RCo) and factor VIII coagulant activity (FVIII:C) to 50 IU/dL or higher and partial response as VWF: RCo or FVIII:C lower than 50 IU/dL after infusion, but at least 3-fold the basal level. Complete response was observed in 83% of patients; partial in 13%; and no response in 4%. Patients with some abnormality of VWF multimeric pattern had significantly lower basal FVIII:C and VWF, lower VWF:RCo/Ag ratio, and less complete responses to desmopressin than patients with a normal multimeric pattern (P =.002). Patients with mutations at codons 1130 and 1205 in the D'-D3 domain had the greatest relative increase, but shortest FVIII and VWF half-lives after infusion. Most partial and nonresponsive patients had mutations in the A1-A3 domains. Response to desmopressin in these VWD patients seemed to be associated with the location of the causative mutation. The presence of subtle multimeric abnormalities did not hamper potential clinically useful responses, as in typical type 1 VWD.}}, author = {{Castaman, Giancarlo and Lethagen, Stefan and Federici, Augusto B and Tosetto, Alberto and Goodeve, Anne and Budde, Ulrich and Batlle, Javier and Meyer, Dominique and Mazurier, Claudine and Fressinaud, Edith and Goudemand, Jenny and Eikenboom, Jeroen and Schneppenheim, Reinhard and Ingerslev, Jorgen and Vorlova, Zdena and Habart, David and Holmberg, Lars and Pasi, John and Hill, Frank and Peake, Ian and Rodeghiero, Francesco}}, issn = {{1528-0020}}, language = {{eng}}, number = {{7}}, pages = {{3531--3539}}, publisher = {{American Society of Hematology}}, series = {{Blood}}, title = {{Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD}}, url = {{http://dx.doi.org/10.1182/blood-2007-08-109231}}, doi = {{10.1182/blood-2007-08-109231}}, volume = {{111}}, year = {{2008}}, }